It successfully achieved silencing of the IDO gene in human dendritic cells (Press release ReGen Therapeutics, AUG 1, 2014, View Source [SID:1234500857]). This is the first experiments in which human cells were utilized in a manner similar to which will be filed with the US FDA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!